Methenamine
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Methenamine: From Urinary Tract Infection to Ureaplasma Urethritis
One-Sentence Summary
Methenamine is a urinary antiseptic classically used for prevention of recurrent urinary tract infections. The TxGNN model predicts it may be effective for Ureaplasma urethritis, but currently only 1 historical publication (no clinical trials) supports this direction, and mechanism-of-action and safety data are not yet available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Urinary tract infection (prophylaxis) — general pharmacological classification; no NZ license record available to confirm formal wording |
| Predicted New Indication | Ureaplasma urethritis |
| TxGNN Prediction Score | 99.79% |
| Evidence Level | L3 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, methenamine belongs to the urinary antiseptic class, and its efficacy in urinary tract infection prophylaxis is well established; mechanistically this antibacterial activity may extend to other lower urogenital tract infections such as Ureaplasma urethritis.
Both the original indication (urinary tract infection) and the predicted indication (Ureaplasma urethritis) involve the lower urogenital tract, giving a plausible anatomical and microbiological rationale for the TxGNN prediction — methenamine's activity depends on local acidic conditions generating an antibacterial effect, which could theoretically inhibit atypical urogenital organisms such as Ureaplasma.
However, this mechanistic plausibility is not yet supported by direct evidence. The single retrieved publication is a 1978 observational survey of women with recurrent urinary tract infection that examined the effect of methenamine hippurate on indigenous urogenital flora — it does not directly test efficacy against Ureaplasma urethritis, and predates modern diagnostic and trial standards.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 640797 | 1978 | Observational survey | Investigative Urology | Survey of 25 women with recurrent UTI found urethral-origin pyuria was common; methenamine hippurate treatment did not alter indigenous urogenital flora |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to a single, decades-old observational study that does not directly test efficacy against Ureaplasma urethritis, with no clinical trials, no mechanism-of-action data, and no safety or New Zealand regulatory data available to support progression.
To proceed, the following is needed:
- Package insert warnings/contraindications (currently a Blocking data gap)
- Confirmed mechanism of action data (currently a High-severity data gap)
- Direct clinical or in-vitro evidence of methenamine activity against Ureaplasma urethritis
- Drug-drug interaction data (current DDI query returned no results)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.